Abdel Saci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abdel Saci has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Jasmine I. Rizzo
9 shared publications- Megan Wind-Rotolo
Bristol-Myers Squibb, Princeton, New Jersey
9 shared publications - Xiaozhong Qian
Daiichi Sankyo, Inc., Basking Ridge, New Jersey
9 shared publications - Dirk Schadendorf
Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
8 shared publications - Donald G. Jackson
Bristol-Myers Squibb, Princeton, NJ 08540, USA
8 shared publications - Frank Stephen Hodi
Dana-Farber Cancer Institute, Boston, MA, USA
8 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma
Supplementary Data from TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma
Supplementary Data from TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma
- Top Cited Papers
- 1 October 2020
- Published by Elsevier in Cancer Cell
- Vol. 38 (4) , 489-499.e3
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
- 1 October 2020
- Published by Elsevier in Cancer Cell
- Vol. 38 (4) , 489-499.e3
Top Cited PapersNivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
- 17 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (548)
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
A combination of ARID1A mutation and CXCL13 expression in baseline tumor tissues improves predictive capability for patients with mUCC receiving ICT.
- 17 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (548)
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
A combination of ARID1A mutation and CXCL13 expression in baseline tumor tissues improves predictive capability for patients with mUCC receiving ICT.